AFP Elevation in Pancreatic Cancer Linked to Advanced Stage

Pancreatic ductal adenocarcinoma, commonly known as PDAC, remains one of the most lethal malignancies in modern oncology, characterized by aggressive progression and a generally poor prognosis. Among the various biological markers used to track disease burden, alpha-fetoprotein, or AFP, has traditionally been associated with hepatocellular carcinoma and germ cell tumors. However, its presence in pancreatic cancer is rare and clinically ambiguous, leaving physicians and researchers with limited guidance on how to interpret elevated levels in this specific context. A recent retrospective study published in the Journal of Cancer Research and Clinical Oncology seeks to clarify the clinicopathological features and prognostic outcomes associated with AFP-elevated PDAC, providing new insights into this uncommon clinical phenotype.

The study, conducted by researchers from the First Affiliated Hospital of Xi’an Jiaotong University in China, retrospectively reviewed patients with pathologically confirmed PDAC treated at the institution over a ten-year period. The primary objective was to identify patients with elevated serum AFP levels at admission and compare their clinical characteristics and survival outcomes against a control group of patients with normal AFP levels. This approach allows for a direct comparison of how the presence of this specific biomarker correlates with disease stage, treatment patterns, and overall survival within a single-center cohort.

The researchers identified a total of 50 patients with AFP-elevated PDAC and 93 patients with AFP-normal PDAC for comparative analysis. In the cohort with elevated AFP, the median serum level was recorded at 9.0 ng/ml, with an interquartile range of 7.6 to 14.3 ng/ml. A striking finding from the clinicopathological assessment was the advanced nature of the disease in this group. The majority of patients with elevated AFP were staged as T4, accounting for 37.2% of the cases, and the staging was predominantly at stage II or higher. This suggests that AFP elevation in PDAC is not merely a random biological fluctuation but is strongly associated with more advanced local disease at the time of diagnosis.

Despite the association with advanced staging, the study did not find a statistically significant difference in overall survival between the AFP-elevated group and the AFP-normal group. This finding is crucial for clinical interpretation, as it indicates that while AFP may signal a more advanced tumor burden, it does not independently predict a worse survival outcome compared to patients with normal AFP levels. The lack of a significant survival difference suggests that other factors, such as the extent of resection and the specific stage of the disease, may play a more dominant role in determining patient outcomes than the presence of AFP alone.

To further investigate the relationship between AFP levels and survival, the researchers employed restricted cubic spline analysis to explore potential nonlinear associations. This statistical method is particularly useful for identifying thresholds or breakpoints where the relationship between a continuous variable and an outcome may change. The analysis suggested a nonlinear association between continuous AFP levels and overall survival, with an estimated breakpoint of approximately 44 ng/ml. This implies that patients with AFP levels below this threshold may have different survival trajectories compared to those with levels above it, although the study notes that this finding requires further validation.

However, the researchers exercised caution in interpreting this nonlinear association. Sensitivity analyses, which included addressing extreme AFP values and applying logarithmic transformations, did not consistently reproduce the breakpoint finding. This inconsistency highlights the complexity of using continuous biomarkers in small cohorts and underscores the need for larger, multicenter studies to confirm these observations. The authors emphasize that the potential nonlinear association should be considered exploratory and should not be used for clinical decision-making without further evidence from broader populations.

The study also examined the impact of treatment patterns on survival outcomes. Patients with AFP-elevated PDAC were more likely to present with unresectable disease due to the advanced T4 staging observed in the cohort. Consequently, the proportion of patients undergoing curative-intent resection was lower in the AFP-elevated group compared to the AFP-normal group. This difference in resectability is a critical confounder when analyzing survival data, as resection status is a well-established independent prognostic factor in PDAC. The authors adjusted for TNM stage and resection status in their multivariable analysis, which further supported the conclusion that AFP elevation itself is not an independent predictor of overall survival.

From a clinical perspective, the findings of this study suggest that elevated AFP in PDAC should be viewed as a marker of advanced disease rather than a standalone prognostic indicator. Physicians encountering patients with PDAC and elevated AFP should be aware that these patients are more likely to have locally advanced tumors, which may influence treatment planning and the feasibility of surgical intervention. However, the absence of a significant survival penalty associated with AFP elevation alone offers a nuanced view that may alleviate some concerns about the biomarker’s direct impact on mortality.

The study has several limitations that must be considered when interpreting the results. As a single-center retrospective study, the sample size is relatively small, which limits the statistical power to detect subtle differences in survival outcomes. Additionally, the retrospective nature of the data may introduce selection bias and missing data, which could affect the generalizability of the findings. The authors acknowledge these limitations and recommend that future studies with larger, multicenter cohorts be conducted to validate the observed associations and to further elucidate the biological mechanisms underlying AFP elevation in PDAC.

In conclusion, this study provides valuable insights into the clinicopathological features of AFP-elevated pancreatic ductal adenocarcinoma. It confirms that this phenotype is rare and frequently presents with advanced disease, but it does not independently worsen overall survival after adjusting for stage and resection status. The potential nonlinear relationship between AFP levels and survival remains an area of interest for future research, but current evidence does not support the use of AFP as a primary prognostic tool in PDAC. These findings contribute to the growing body of knowledge on biomarkers in pancreatic cancer and highlight the importance of integrating multiple clinical factors in patient management.

Subject of Research: Clinicopathological features and prognostic outcomes of AFP-elevated pancreatic ductal adenocarcinoma

Article Title: Clinicopathological features and prognostic outcomes in pancreatic ductal adenocarcinoma with elevated alpha fetoprotein: a single-center retrospective study

Article References: Liu, H., Cao, R., Zhang, S., Wei, K., Wei, W., Yang, S., Li, B., Ma, F., Wu, J., Feng, Z., Wang, F., Wu, S., Zhou, C., He, H., Cheng, Y., Wang, Z., Ma, Q., Wu, Z., & Han, L. (2026). Clinicopathological features and prognostic outcomes in pancreatic ductal adenocarcinoma with elevated alpha fetoprotein: a single-center retrospective study. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06643-1

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06643-1

Keywords: pancreatic cancer, alpha-fetoprotein, PDAC, prognosis, biomarkers, oncology, retrospective study, clinical outcomes, Clinicopathological, features, prognostic, outcomes